Trial Profile
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2016
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel; Thiotepa
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms SUBITO
- 03 Oct 2016 New trial record